ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic
The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognit...
Gespeichert in:
| Veröffentlicht in: | Blood 2020-05, Vol.135 (21), p.1829-1832 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1832 |
|---|---|
| container_issue | 21 |
| container_start_page | 1829 |
| container_title | Blood |
| container_volume | 135 |
| creator | Yahalom, Joachim Dabaja, Bouthaina Shbib Ricardi, Umberto Ng, Andrea Mikhaeel, N. George Vogelius, Ivan R. Illidge, Tim Qi, Shunan Wirth, Andrew Specht, Lena |
| description | The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognition of the need to also reduce the exposure of patients and staff to potential infection with COVID-19, the ILROG task force has made recommendations for alternative radiation treatment schemes. The emphasis is on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. The guidance is informed by adhering to acceptable radiobiological parameters and clinical tolerability. The options for delaying or omitting RT in some hematological categories are also discussed. |
| doi_str_mv | 10.1182/blood.2020006028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7243146</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120620109</els_id><sourcerecordid>2388828886</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-6bcd95f091cee4fb06801ae83ce228a8dd733ee7543d9657f2abd00e6308b4a83</originalsourceid><addsrcrecordid>eNp1kc2P0zAQxS0EYsvCnRPykUuW8UcShwMSKrBbqVIlBFwtx56khsQudrJS_3vS7bLAgcNopPHvvbHmEfKSwRVjir9phxjdFQcOABVw9YisWMlVAcvkMVmdpoVsanZBnuX8HYBJwcun5EJwXpe1hBX5sdl-3l1THDH1GOyR9rN3OPiAmXYx0WScN5OPgU57TOZwpLGjexzNFIfYe2sGOprB98EE6xeNm5MP_Qmm6923zYeCNfRggsPR2-fkSWeGjC_u-yX5-unjl_VNsd1db9bvt4WVsp6KqrWuKTtomEWUXQuVAmZQCYucK6Ocq4VArEspXFOVdcdN6wCwEqBaaZS4JO_Ovoe5HdFZDFMygz4kP5p01NF4_e9L8Hvdx1tdcymYrBaD1_cGKf6cMU969NniMJiAcc6aC6UUX-qEwhm1KeacsHtYw0CfMtJ3Gek_GS2SV39_70HwO5QFeHsGcDnSrcek83LbYNH5hHbSLvr_u_8CakOjUQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2388828886</pqid></control><display><type>article</type><title>ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Yahalom, Joachim ; Dabaja, Bouthaina Shbib ; Ricardi, Umberto ; Ng, Andrea ; Mikhaeel, N. George ; Vogelius, Ivan R. ; Illidge, Tim ; Qi, Shunan ; Wirth, Andrew ; Specht, Lena</creator><creatorcontrib>Yahalom, Joachim ; Dabaja, Bouthaina Shbib ; Ricardi, Umberto ; Ng, Andrea ; Mikhaeel, N. George ; Vogelius, Ivan R. ; Illidge, Tim ; Qi, Shunan ; Wirth, Andrew ; Specht, Lena ; on behalf of the International Lymphoma Radiation Oncology Group (ILROG)</creatorcontrib><description>The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognition of the need to also reduce the exposure of patients and staff to potential infection with COVID-19, the ILROG task force has made recommendations for alternative radiation treatment schemes. The emphasis is on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. The guidance is informed by adhering to acceptable radiobiological parameters and clinical tolerability. The options for delaying or omitting RT in some hematological categories are also discussed.</description><identifier>ISSN: 0006-4971</identifier><identifier>ISSN: 1528-0020</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.2020006028</identifier><identifier>PMID: 32275740</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Betacoronavirus - isolation & purification ; Coronavirus Infections - epidemiology ; Coronavirus Infections - prevention & control ; COVID-19 ; Hematologic Neoplasms - radiotherapy ; Humans ; Lymphoma - radiotherapy ; Pandemics - prevention & control ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - prevention & control ; Radiotherapy Dosage ; Radiotherapy Planning, Computer-Assisted ; Risk Factors ; SARS-CoV-2 ; Special Report ; Time Factors</subject><ispartof>Blood, 2020-05, Vol.135 (21), p.1829-1832</ispartof><rights>2020 American Society of Hematology</rights><rights>2020 by The American Society of Hematology.</rights><rights>Copyright © 2020 American Society of Hematology. 2020 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-6bcd95f091cee4fb06801ae83ce228a8dd733ee7543d9657f2abd00e6308b4a83</citedby><cites>FETCH-LOGICAL-c447t-6bcd95f091cee4fb06801ae83ce228a8dd733ee7543d9657f2abd00e6308b4a83</cites><orcidid>0000-0002-6902-2190 ; 0000-0002-8877-1218 ; 0000-0003-0359-0328</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,778,782,883,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32275740$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yahalom, Joachim</creatorcontrib><creatorcontrib>Dabaja, Bouthaina Shbib</creatorcontrib><creatorcontrib>Ricardi, Umberto</creatorcontrib><creatorcontrib>Ng, Andrea</creatorcontrib><creatorcontrib>Mikhaeel, N. George</creatorcontrib><creatorcontrib>Vogelius, Ivan R.</creatorcontrib><creatorcontrib>Illidge, Tim</creatorcontrib><creatorcontrib>Qi, Shunan</creatorcontrib><creatorcontrib>Wirth, Andrew</creatorcontrib><creatorcontrib>Specht, Lena</creatorcontrib><creatorcontrib>on behalf of the International Lymphoma Radiation Oncology Group (ILROG)</creatorcontrib><title>ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic</title><title>Blood</title><addtitle>Blood</addtitle><description>The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognition of the need to also reduce the exposure of patients and staff to potential infection with COVID-19, the ILROG task force has made recommendations for alternative radiation treatment schemes. The emphasis is on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. The guidance is informed by adhering to acceptable radiobiological parameters and clinical tolerability. The options for delaying or omitting RT in some hematological categories are also discussed.</description><subject>Betacoronavirus - isolation & purification</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronavirus Infections - prevention & control</subject><subject>COVID-19</subject><subject>Hematologic Neoplasms - radiotherapy</subject><subject>Humans</subject><subject>Lymphoma - radiotherapy</subject><subject>Pandemics - prevention & control</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Pneumonia, Viral - prevention & control</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy Planning, Computer-Assisted</subject><subject>Risk Factors</subject><subject>SARS-CoV-2</subject><subject>Special Report</subject><subject>Time Factors</subject><issn>0006-4971</issn><issn>1528-0020</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc2P0zAQxS0EYsvCnRPykUuW8UcShwMSKrBbqVIlBFwtx56khsQudrJS_3vS7bLAgcNopPHvvbHmEfKSwRVjir9phxjdFQcOABVw9YisWMlVAcvkMVmdpoVsanZBnuX8HYBJwcun5EJwXpe1hBX5sdl-3l1THDH1GOyR9rN3OPiAmXYx0WScN5OPgU57TOZwpLGjexzNFIfYe2sGOprB98EE6xeNm5MP_Qmm6923zYeCNfRggsPR2-fkSWeGjC_u-yX5-unjl_VNsd1db9bvt4WVsp6KqrWuKTtomEWUXQuVAmZQCYucK6Ocq4VArEspXFOVdcdN6wCwEqBaaZS4JO_Ovoe5HdFZDFMygz4kP5p01NF4_e9L8Hvdx1tdcymYrBaD1_cGKf6cMU969NniMJiAcc6aC6UUX-qEwhm1KeacsHtYw0CfMtJ3Gek_GS2SV39_70HwO5QFeHsGcDnSrcek83LbYNH5hHbSLvr_u_8CakOjUQ</recordid><startdate>20200521</startdate><enddate>20200521</enddate><creator>Yahalom, Joachim</creator><creator>Dabaja, Bouthaina Shbib</creator><creator>Ricardi, Umberto</creator><creator>Ng, Andrea</creator><creator>Mikhaeel, N. George</creator><creator>Vogelius, Ivan R.</creator><creator>Illidge, Tim</creator><creator>Qi, Shunan</creator><creator>Wirth, Andrew</creator><creator>Specht, Lena</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6902-2190</orcidid><orcidid>https://orcid.org/0000-0002-8877-1218</orcidid><orcidid>https://orcid.org/0000-0003-0359-0328</orcidid></search><sort><creationdate>20200521</creationdate><title>ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic</title><author>Yahalom, Joachim ; Dabaja, Bouthaina Shbib ; Ricardi, Umberto ; Ng, Andrea ; Mikhaeel, N. George ; Vogelius, Ivan R. ; Illidge, Tim ; Qi, Shunan ; Wirth, Andrew ; Specht, Lena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-6bcd95f091cee4fb06801ae83ce228a8dd733ee7543d9657f2abd00e6308b4a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Betacoronavirus - isolation & purification</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronavirus Infections - prevention & control</topic><topic>COVID-19</topic><topic>Hematologic Neoplasms - radiotherapy</topic><topic>Humans</topic><topic>Lymphoma - radiotherapy</topic><topic>Pandemics - prevention & control</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Pneumonia, Viral - prevention & control</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy Planning, Computer-Assisted</topic><topic>Risk Factors</topic><topic>SARS-CoV-2</topic><topic>Special Report</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yahalom, Joachim</creatorcontrib><creatorcontrib>Dabaja, Bouthaina Shbib</creatorcontrib><creatorcontrib>Ricardi, Umberto</creatorcontrib><creatorcontrib>Ng, Andrea</creatorcontrib><creatorcontrib>Mikhaeel, N. George</creatorcontrib><creatorcontrib>Vogelius, Ivan R.</creatorcontrib><creatorcontrib>Illidge, Tim</creatorcontrib><creatorcontrib>Qi, Shunan</creatorcontrib><creatorcontrib>Wirth, Andrew</creatorcontrib><creatorcontrib>Specht, Lena</creatorcontrib><creatorcontrib>on behalf of the International Lymphoma Radiation Oncology Group (ILROG)</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yahalom, Joachim</au><au>Dabaja, Bouthaina Shbib</au><au>Ricardi, Umberto</au><au>Ng, Andrea</au><au>Mikhaeel, N. George</au><au>Vogelius, Ivan R.</au><au>Illidge, Tim</au><au>Qi, Shunan</au><au>Wirth, Andrew</au><au>Specht, Lena</au><aucorp>on behalf of the International Lymphoma Radiation Oncology Group (ILROG)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2020-05-21</date><risdate>2020</risdate><volume>135</volume><issue>21</issue><spage>1829</spage><epage>1832</epage><pages>1829-1832</pages><issn>0006-4971</issn><issn>1528-0020</issn><eissn>1528-0020</eissn><abstract>The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognition of the need to also reduce the exposure of patients and staff to potential infection with COVID-19, the ILROG task force has made recommendations for alternative radiation treatment schemes. The emphasis is on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. The guidance is informed by adhering to acceptable radiobiological parameters and clinical tolerability. The options for delaying or omitting RT in some hematological categories are also discussed.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32275740</pmid><doi>10.1182/blood.2020006028</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-6902-2190</orcidid><orcidid>https://orcid.org/0000-0002-8877-1218</orcidid><orcidid>https://orcid.org/0000-0003-0359-0328</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2020-05, Vol.135 (21), p.1829-1832 |
| issn | 0006-4971 1528-0020 1528-0020 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7243146 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Betacoronavirus - isolation & purification Coronavirus Infections - epidemiology Coronavirus Infections - prevention & control COVID-19 Hematologic Neoplasms - radiotherapy Humans Lymphoma - radiotherapy Pandemics - prevention & control Pneumonia, Viral - epidemiology Pneumonia, Viral - prevention & control Radiotherapy Dosage Radiotherapy Planning, Computer-Assisted Risk Factors SARS-CoV-2 Special Report Time Factors |
| title | ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T06%3A19%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ILROG%20emergency%20guidelines%20for%20radiation%20therapy%20of%20hematological%20malignancies%20during%20the%20COVID-19%20pandemic&rft.jtitle=Blood&rft.au=Yahalom,%20Joachim&rft.aucorp=on%20behalf%20of%20the%20International%20Lymphoma%20Radiation%20Oncology%20Group%20(ILROG)&rft.date=2020-05-21&rft.volume=135&rft.issue=21&rft.spage=1829&rft.epage=1832&rft.pages=1829-1832&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.2020006028&rft_dat=%3Cproquest_pubme%3E2388828886%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2388828886&rft_id=info:pmid/32275740&rft_els_id=S0006497120620109&rfr_iscdi=true |